BofA raised the firm’s price target on Belite Bio (BLTE) to $200 from $195 and keeps a Buy rating on the shares. After the company reported FY25 results and provided a comprehensive update on their programs, the firm remains bullish on the large commercial opportunity for tinlarebant given the high unmet need and positive data supporting its clinical benefit, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
- Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran
- Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win
- Belite Bio sees Q4 adjusted EPS (38c), consensus (54c)
- Belite Bio sees FY25 adjusted EPS ($1.15) vs. ($89c) last year